Xenetic Biosciences
XBIO
7 hedge funds and large institutions have $73.8K invested in Xenetic Biosciences in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
22% more capital invested
Capital invested by funds: $60.7K → $73.8K (+$13.1K)
0.17% more ownership
Funds ownership: 1.1% → 1.27% (+0.17%)
0% more funds holding
Funds holding: 7 → 7 (0)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$363 |
| 2 |
Morgan Stanley
New York
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $41.5K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $11.6K | +$10.6K | +2,770 | +908% |
|
|
JEST
3
JTC Employer Solutions Trustee
St Helier,
Jersey
| $10K | – | – | – |
|
|
SPIA
4
Steward Partners Investment Advisory
New York
| $7.16K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.49K | -$363 | -95 | -9% |
|
6
Wells Fargo
San Francisco,
California
| $41 | – | – | – |
|
|
7
Morgan Stanley
New York
| $4 | -$4 | -1 | -50% |
|
XBIO Hedge Fund Activity: Q1 2024 in Review
7 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2024, worth a combined $73.8K — up 22% from $60.7K a quarter earlier.
Fund positioning in XBIO was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $10.6K. The largest seller was Tower Research Capital (TRC), cutting an estimated $363.
- 7 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $73.8K of Xenetic Biosciences stock for Q1 2024, up 22% quarter-over-quarter.
- 0 funds opened new Xenetic Biosciences positions in Q1 2024 and 0 closed out.
- The largest Xenetic Biosciences buyer in Q1 2024 was UBS Group, an estimated $10.6K added.
- The largest Xenetic Biosciences seller in Q1 2024 was Tower Research Capital (TRC), an estimated $363 sold.
Based on aggregated 13F filings for Q1 2024.